Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers.
- Authors
- Zhu, A Z X; Zhou, Q; Cox, L S; David, S P; Ahluwalia, J S; Benowitz, N L; Tyndale, R F
- Year
- 2014
- Journal
- Clinical pharmacology and therapeutics
- PMID
- 24733007
- DOI
- 10.1038/clpt.2014.88
- PMCID
- PMC4111775
Associations between CHRNA5-A3-B4 variants and smoking behaviors exist; however, the association with smoking abstinence is less understood, particularly that among African Americans. In 1,295 African Americans enrolled in two clinical trials, we investigated the association between CHRNA5-A3-B4 and smoking abstinence. The rs2056527(A) allele was associated with lower abstinence with active pharmacotherapy (during treatment: odds ratio (OR) = 0.42, P < 0.001; end of treatment (EOT): OR = 0.55, P = 0.004), or with nicotine gum alone (during treatment: OR = 0.31, P < 0.001; EOT: OR = 0.51, P = 0.02), but not significantly with bupropion, although similar directions and magnitudes were observed (during treatment: OR = 0.54, P = 0.05; EOT: OR = 0.59, P = 0.08). In addition, the rs588765(T) allele was associated with abstinence with gum during treatment (OR = 2.31, P < 0.01). The SNP rs16969968 occurred at a low frequency and was not consistently associated with abstinence. CHRNA5-A3-B4 variants were not associated with tobacco consumption, and adjustments for smoking behaviors did not alter the associations with smoking abstinence. Together, our data suggest that among African Americans, CHRNA5-A3-B4 variants are not associated with baseline smoking but can influence smoking abstinence during active pharmacotherapy.
The associations (dominant model) between CHRNA5-A3-B5 variants and smoking abstinence in African American smokers. A) Participants who received active nicotine gum treatment (Study 1). B) Participants who received active bupropion treatment (Study 2). C) Participants who received active pharmacological treatments (combined analysis). D) Participants who received placebo (combined analysis). P-values below 0.0125 were considered statistically significant due to multiple comparison adjustments. Statistically significant values are bolded.
The βAβ allele of rs2036527 was associated with lower smoking cessation rates in African American smokers receiving active pharmacological treatment. A) Participants in who received nicotine gum or placebo (Study 1). B) Participants who received active bupropion or placebo (Study 2). C) Participants who received active pharmacological treatments (combined analysis). ORunadj. = unadjusted odds ratio of quitting for the GA&AA genotype group compared to the GG genotype. ORadj.= odds ratio of quitting for the GA&AA genotype group compared to the GG genotype after adjusting for age, sex, baseline CPD, menthol status and type of counseling session. There was also a significant treatment (combined active vs. combined placebo) by rs2036527 genotype interaction during treatment (OR=0.43, P=0.01). The OR and P-values are shown for all comparisons with ORs smaller than 0.7 or greater than 1.4. P-values below 0.0125 were considered statistically significant due to multiple comparison adjustments. Statistically significant values are bolded. N represents the number of participants.
The βTβ allele of rs588765 was associated with smoking abstinence in African American smokers receiving active pharmacological treatment. A) Participants in who received nicotine gum or placebo (Study 1). B) Participants who received active bupropion or placebo (Study 2). C) Participants who received active pharmacological treatments (combined analysis). ORunadj. = unadjusted odds ratio of quitting for the CT&TT genotype group compared to the CC genotype. ORadj.= odds ratio of quitting for the CT&TT genotype group compared to the CC genotype after adjusting for age, sex, baseline CPD, menthol status and type of counseling sessions. There was also a significant treatment (combined active vs. combined placebo) by rs588765 genotype interaction during treatment (OR=3.75, P<0.001). The OR and P-values are shown for all comparisons with ORs smaller than 0.7 or greater than 1.4. P-values below 0.0125 were considered statistically significant due to multiple comparison adjustments. Statistically significant values are bolded. N represents the number of participants.
Rs16969968 was not consistently associated with smoking abstinence in African American smokers receiving active pharmacological treatment. A) Participants in who received nicotine gum or placebo (Study 1). B) Participants who received active bupropion or placebo (Study 2). C) Participants who received active pharmacological treatments (combined analysis). ORunadj. = unadjusted odds ratio of quitting for the GA&AA genotype group compared to the GG genotype. ORadj.= odds ratio of quitting for the GA&AA genotype group compared to the GG genotype after adjusting for age, sex, baseline CPD, menthol status and type of counseling sessions. The OR and P-values are shown for all comparisons with ORs smaller than 0.7 or greater than 1.4. P-values below 0.0125 were considered statistically significant due to multiple comparison adjustments. Statistically significant values are bolded. N represents the number of participants.
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A novel phenotype imputation method with copula model. | Zhang J et al. | β | 2024 | β |
| Antidepressants for smoking cessation. | Hajizadeh A et al. | β | 2023 | β |
| A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations. | Prom-Wormley EC et al. | β | 2023 | β |
| Genomic medicine to reduce tobacco and related disorders: Translation to precision prevention and treatment. | Chen LS et al. | β | 2023 | β |
| A systematic review of genetic variation within nicotinic acetylcholine receptor genes and cigarette smoking cessation. | Jones SK et al. | β | 2022 | β |
| Comparative Assessment of Outcomes in Drug Treatment for Smoking Cessation and Role of Genetic Polymorphisms of Human Nicotinic Acetylcholine Receptor Subunits. | Muderrisoglu A et al. | β | 2022 | β |
| Antidepressants for smoking cessation. | Howes S et al. | β | 2020 | β |
| Genetics of Smoking Behaviors in American Indians. | Henderson JA et al. | β | 2020 | β |
| Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial. | Chen LS et al. | β | 2020 | β |
| Joint analysis of multiple phenotypes using a clustering linear combination method based on hierarchical clustering. | Li X et al. | β | 2020 | β |
| Translational Molecular Approaches in Substance Abuse Research. | Fulton SL et al. | β | 2020 | β |
| A clustering linear combination approach to jointly analyze multiple phenotypes for GWAS. | Sha Q et al. | β | 2019 | β |
| Joint Analysis of Multiple Phenotypes in Association Studies based on Cross-Validation Prediction Error. | Yang X et al. | β | 2019 | β |
| Neurogenetic determinants and mechanisms of addiction to nicotine and smoked tobacco. | Sharp BM et al. | β | 2019 | β |
| A hierarchical clustering method for dimension reduction in joint analysis of multiple phenotypes. | Liang X et al. | β | 2018 | β |
| A novel method to test associations between a weighted combination of phenotypes and genetic variants. | Zhu H et al. | β | 2018 | β |
| From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. | Salloum NC et al. | β | 2018 | β |
| Human Genetics of Addiction: New Insights and Future Directions. | Hancock DB et al. | β | 2018 | β |
| Kynurenine 3-Monooxygenase Gene Associated With Nicotine Initiation and Addiction: Analysis of Novel Regulatory Features at 5' and 3'-Regions. | Aziz HA et al. | β | 2018 | β |
| Pathways to precision medicine in smoking cessation treatments. | Chen LS et al. | β | 2018 | β |
| Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. | Bierut LJ et al. | β | 2018 | β |
| The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. | Saccone NL et al. | β | 2018 | β |
| Toward the implementation of genomic applications for smoking cessation and smoking-related diseases. | Ramsey AT et al. | β | 2018 | β |
| Associations between single nucleotide polymorphisms in RYBP and the prognosis of hepatocellular carcinoma in a Chinese population. | Zhu X et al. | β | 2017 | β |
| Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. | Taghavi T et al. | β | 2017 | β |
| Oral Cell DNA Adducts as Potential Biomarkers for Lung Cancer Susceptibility in Cigarette Smokers. | Hecht SS | β | 2017 | β |
| Pharmacogenetic Optimization of Smoking Cessation Treatment. | Chenoweth MJ et al. | β | 2017 | β |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | β | 2017 | β |
| Relative contribution of genetic, individual, and self-efficacy factors to smoking cessation in a Chinese rural population. | Wang Q et al. | β | 2017 | β |
| An Adaptive Fisher's Combination Method for Joint Analysis of Multiple Phenotypes in Association Studies. | Liang X et al. | β | 2016 | β |
| Association between variants in nicotinic acetylcholine receptor genes and smoking cessation in a Chinese rural population. | Wang Q et al. | β | 2016 | β |
| Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity. | Benowitz NL et al. | β | 2016 | β |
| Gene by Environment Investigation of Incident Lung Cancer Risk in African-Americans. | David SP et al. | β | 2016 | β |
| Genome-wide association study confirms lung cancer susceptibility loci on chromosomes 5p15 and 15q25 in an African-American population. | Zanetti KA et al. | β | 2016 | β |
| Nicotinic acetylcholine receptors: upregulation, age-related effects and associations with drug use. | Melroy-Greif WE et al. | β | 2016 | β |
| Perceptions of pharmacogenetic research to guide tobacco cessation by patients, providers and leaders in a tribal healthcare setting. | Avey JP et al. | β | 2016 | β |
| Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. | Chen LS et al. | β | 2015 | β |
| Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. | Tyndale RF et al. | β | 2015 | β |
| Pharmacogenetics of nicotine and associated smoking behaviors. | Tanner JA et al. | β | 2015 | β |
| The value of control conditions for evaluating pharmacogenetic effects. | Chen LS et al. | β | 2015 | β |